Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

A Review of the Key Clinical Trials of 2014

A Review of the Key Clinical Trials of 2014 Cardiol Ther (2015) 4:5–23 DOI 10.1007/s40119-015-0036-0 REVIEW • • Peter McKavanagh Claire McCune Ian B. Menown To view enhanced content go to www.cardiologytherapy-open.com Received: January 23, 2015 / Published online: March 27, 2015 The Author(s) 2015. This article is published with open access at Springerlink.com Selection criteria were trials of broad relevance ABSTRACT to the cardiology community, those with Introduction: Over the last year, multiple, potential to change current practice and those potentially practice-changing, cardiology trials with potential to guide further phase III or studies have been published or presented at research. international meetings including the American Results: In this paper, the authors describe and College of Cardiology, European Association for place in clinical context, new HF, data Percutaneous Cardiovascular Interventions, including neprilysin inhibitors, intravenous European Society of Cardiology, Transcatheter ferric carboxymaltose, potassium-absorbing Cardiovascular Therapeutics, Heart Failure compounds, quadripolar leads for cardiac Congress, Heart Rhythm Society, Heart Failure resynchronization therapy and intraventricular Society of America, American Society of device intervention. New trial data are also Hypertension and the American Heart described for acute coronary syndromes Association. (clopidogrel, prasugrel, ticagrelor), stable Methods: Clinical trial results presented at coronary artery disease (ivabradine), major cardiology conferences during 2014 percutaneous coronary intervention (the http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Cardiology and Therapy Springer Journals

A Review of the Key Clinical Trials of 2014

Download PDF
19 pages

Loading next page...
 
/lp/springer-journals/a-review-of-the-key-clinical-trials-of-2014-8Bfg1eIXYi
Publisher
Springer Journals
Copyright
Copyright © 2015 by The Author(s)
Subject
Medicine & Public Health; Internal Medicine; Cardiology
ISSN
2193-8261
eISSN
2193-6544
DOI
10.1007/s40119-015-0036-0
pmid
25814425
Publisher site
See Article on Publisher Site

Abstract

Cardiol Ther (2015) 4:5–23 DOI 10.1007/s40119-015-0036-0 REVIEW • • Peter McKavanagh Claire McCune Ian B. Menown To view enhanced content go to www.cardiologytherapy-open.com Received: January 23, 2015 / Published online: March 27, 2015 The Author(s) 2015. This article is published with open access at Springerlink.com Selection criteria were trials of broad relevance ABSTRACT to the cardiology community, those with Introduction: Over the last year, multiple, potential to change current practice and those potentially practice-changing, cardiology trials with potential to guide further phase III or studies have been published or presented at research. international meetings including the American Results: In this paper, the authors describe and College of Cardiology, European Association for place in clinical context, new HF, data Percutaneous Cardiovascular Interventions, including neprilysin inhibitors, intravenous European Society of Cardiology, Transcatheter ferric carboxymaltose, potassium-absorbing Cardiovascular Therapeutics, Heart Failure compounds, quadripolar leads for cardiac Congress, Heart Rhythm Society, Heart Failure resynchronization therapy and intraventricular Society of America, American Society of device intervention. New trial data are also Hypertension and the American Heart described for acute coronary syndromes Association. (clopidogrel, prasugrel, ticagrelor), stable Methods: Clinical trial results presented at coronary artery disease (ivabradine), major cardiology conferences during 2014 percutaneous coronary intervention (the

Journal

Cardiology and Therapy – Springer Journals

Published: Mar 27, 2015

References

  • Careers in cardiovascular research
    Fuster, V; Zee, S; Elmariah, S; Bonow, RO
  • Angiotensin-neprilysin inhibition versus enalapril in heart failure
    McMurray, JJ; Packer, M; Desai, AS; Gong, J; Lefkowitz, MP; Rizkala, AR
  • Left ventricular remodeling after myocardial infarction: pathophysiology and therapy
    Sutton, MG; Sharpe, N
  • PRAMI Investigators. Randomized trial of preventive angioplasty in myocardial infarction
    Wald, DS; Morris, JK; Wald, NJ; Chase, AJ; Edwards, RJ; Hughes, LO
  • Complete vs culprit-only revascularization for patients with multivessel disease undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: a systematic review and meta-analysis
    Bainey, KR; Mehta, SR; Lai, T; Welsh, RC
  • Thrombus aspiration during ST-segment elevation myocardial infarction (TASTE Trial)
    Fröbert, O; Lagerqvist, B; Olivecrona, GK; Omerovic, E; Gudnason, T; Maeng, M
  • Outcomes 1 year after thrombus aspiration for myocardial infarction
    Lagerqvist, B; Fröbert, O; Olivecrona, GK; Gudnason, T; Maeng, M; Alström, P
  • Thrombus Aspiration during Percutaneous coronary intervention in Acute myocardial infarction Study (TAPAS)—study design
    Svilaas, T; Horst, IC; Zijlstra, F
  • Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) randomized, noninferiority trial
    Serruys, PW; Farooq, V; Kalesan, B; Vries, T; Buszman, P; Linke, A; Ischinger, T; Klauss, V; Eberli, F; Wijns, W; Morice, MC; Mario, C; Corti, R; Antoni, D; Sohn, HY; Eerdmans, P; Rademaker-Havinga, T; Es, GA; Meier, B; Jüni, P; Windecker, S
  • Impact of renal denervation on 24-hour ambulatory blood pressure: results from SYMPLICITY HTN-3
    Bakris, GL; Townsend, RR; Liu, M; Cohen, SA; D’Agostino, R; Flack, JM
  • First Report of the Global SYMPLICITY Registry on the effect of renal artery denervation in patients with uncontrolled hypertension
    Böhm, M; Mahfoud, F; Ukena, C; Hoppe, UC; Narkiewicz, K; Negoita, M; Ruilope, L; Schlaich, MP; Schmieder, RE; Whitbourn, R; Williams, B; Zeymer, U; Zirlik, A; Mancia, G
  • Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents
    Mauri, L; Kereiakes, DJ; Yeh, RW
  • 2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI)
    Windecker, S; Kolh, P; Alfonso, F; Collet, JP; Cremer, J; Falk, V
  • Long-term outcomes of inoperable patients with aortic stenosis randomly assigned to transcatheter aortic valve replacement or standard therapy
    Kapadia, SR; Tuzcu, EM; Makkar, RR; Svensson, LG; Agarwal, S; Kodali, S
  • Transcatheter aortic-valve replacement with a self-expanding prosthesis
    Adams, DH; Popma, JJ; Reardon, MJ; Yakubov, SJ; Coselli, JS; Deeb, GM
  • A simple risk tool (the OBSERVANT score) for prediction of 30-day mortality after transcatheter aortic valve replacement
    Capodanno, D; Barbanti, M; Tamburino, C; D’Errigo, P; Ranucci, M; Santoro, G
  • Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial
    Fox, K; Ford, I; Steg, PG; Tendera, M; Robertson, M; Ferrari, R
  • Ferrari R; SIGNIFY Investigators. Ivabradine in stable coronary artery disease without clinical heart failure
    Fox, K; Ford, I; Steg, PG; Tardif, JC; Tendera, M
  • Fractional flow reserve-guided PCI for stable coronary artery disease
    Bruyne, B; Fearon, WF; Pijls, NH; Barbato, E; Tonino, P; Piroth, Z
  • Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure
    Bristow, MR; Saxon, LA; Boehmer, J; Krueger, S; Kass, DA; Marco, T
  • The effect of cardiac resynchronization on morbidity and mortality in heart failure
    Cleland, JG; Daubert, JC; Erdmann, E; Freemantle, N; Gras, D; Kappenberger, L
  • Predictive factors of difficult implantation procedure in cardiac resynchronization therapy
    Bisch, L; Costa, A; Dauphinot, V; Romeyer-Bouchard, C; Khris, L; M’Baye, A
  • Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay
    Cazeau, S; Leclercq, C; Lavergne, T; Walker, S; Varma, C; Linde, C
  • Permanent leadless cardiac pacing: results of the LEADLESS trial
    Reddy, VY; Knops, RE; Sperzel, J; Miller, MA; Petru, J; Simon, J
  • Adverse prognosis of incidentally detected ambulatory atrial fibrillation. A cohort study
    Martinez, C; Katholing, A; Freedman, SB
  • Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial
    Moriarty, PM; Jacobson, TA; Bruckert, E; Thompson, PD; Guyton, JR; Baccara-Dinet, MT; Gipe, D
  • Effect of screening for coronary artery disease using CT angiography on mortality and cardiac events in high-risk patients with diabetes: the FACTOR-64 Randomized Clinical Trial
    Muhlestein, JB; Lappé, DL; Lima, JA; Rosen, BD; May, HT; Knight, S; Bluemke, DA; Towner, SR; Le, V; Bair, TL; Vavere, AL; Anderson, JL